STOCK TITAN
  1. Home
  2. News
  3. STIM

Neuronetics to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter financial and operating results prior to market open on Tuesday, November 9, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at ir.neuronetics.com. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 3891687, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com. 

Investor Contact:

Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com 

Media Contact:

EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com 


Stock STIM logo
Neuronetics, Inc.

NASDAQ:STIM

STIM Rankings

#4240 Ranked by Market Cap
#5101 Ranked by Stock Gains
N/A Ranked by Dividends

STIM Latest News

Apr 23, 2024
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
Apr 10, 2024
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Mar 27, 2024
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 25, 2024
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
Mar 7, 2024
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

STIM Stock Data

104.91M
21.29M
6.62%
65.25%
0.32%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MALVERN

About STIM

with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.